Article

Efficacy of lorlatinib treatment in ALK -rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status

2020-12-29

Abstract excerpt

Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) designed to penetrate the blood brain barrier. We report 2 cases of patients with ALK -rearrangement non-small cell carcinoma associated with severe symptomatic CNS metastases and poor performance status. Treatment with lorlatinib improved their neurological condition and performance status.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bdb9e0dd-e955-55ad-a282-e1917ca336af
DOI: 10.22541/au.160925134.48293612/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy of lorlatinib treatment in ALK -rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance statusDOI 10.22541/au.160925134.48293612/v1Read

Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer.Semantic proximity Read

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to dateSemantic proximity Read

A user’s guide to lorlatinibSemantic proximity Read

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.Semantic proximity Read

Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.Semantic proximity Read

Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.Semantic proximity Read

Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment-naive patients with advanced EGFR mutation-positive non-small cell lung cancer: Protocol of an open-label, single-arm phase II trial.Semantic proximity Read

Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read

Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.Semantic proximity Read

The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.Semantic proximity Read

Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study.Semantic proximity Read

Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.Semantic proximity Read